Belgian biotech firm to roll out coronavirus antibody tests

Image
AFP Liege
Last Updated : Apr 21 2020 | 9:00 PM IST

A Belgian biotech firm has started producing tests to rapidly detect antibodies against coronavirus infections, part of a push several countries are making to determine who might be immune.

The Liege-based company, ZenTech, told AFP Tuesday it has started making tens of thousands of the government-certified tests and plans to ramp up output to eventually make up to three million per month.

Founder and CEO Jean-Claude Havaux said diagnosis takes just 10-15 minutes and "sensitivity is 100 percent -- meaning all patients who have COVID-19 antibodies, we see them with our test".

He emphasised that the test kits were only for medical professionals, first in Belgium and then later in other countries in the EU and beyond. They are not for the public to use at home.

"We don't want, and don't intend for, these tests to be used by just anybody. It's not a pregnancy test," said Havaux.

"It's really pretty complicated to carry out and to interpret the results." Antibody, or serology, tests are seen as a crucial tool for determining who has had COVID-19 -- especially non-symptomatic carriers -- and could therefore be immune to it, at least for a time. Such tests could possibly pave the way to allowing people to return to work as countries mull easing widespread lockdown measures.

That could be especially important for healthcare workers on the front line of the novel coronavirus pandemic.

As a result, labs in several countries are racing to roll out huge numbers of reliable testing kits.

But the World Health Organization has warned that while reliable testing is welcome, the presence of COVID-19 antibodies is not proof that an individual is immune. Even if there was immunity, it says, it is unknown how long it might last.

Dr Pascale Huynen, clinic head of the microbiology unit in Liege's university hospital -- which confirmed ZenTech's test was reliable to 97 percent -- also underscored the point. "Nobody knows if the (COVID-19) antibodies are protective," she said.

She added that scientists also do not know how long immunity could last, or whether the new coronavirus might mutate around any initial immunity, as happens with the flu.

"This is a virus that we don't know very well," she said. ZenTech's test, she said, simply indicates whether a patient has "come into contact" with COVID-19 with a positive or negative result. It does not show the level of antibody response.

But that in itself is useful for determining the spread of the virus in a population, and for patients who have not received a nasal swab tests that detect whether a person is in the infectious phase, thought to last around two weeks.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 21 2020 | 9:00 PM IST

Next Story